Anti-inflammatory effects of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis heterozygous for F508del
PLOS ONE · 31.05.2024 · 19 (5) · e0304555
DOI: 10.1371/journal.pone.0304555 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 31.05.2024. Verfasst von Heledd H Jarosz-Griffiths und 8 weiteren Autor:innen. Beteiligte Einrichtung: Leeds Institute of Medical Research, University of Leeds, Leeds, United Kingdom. Hauptthemen laut MEDLINE: Cystic Fibrosis, Benzodioxoles, Aminophenols, Indoles. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cystic Fibrosis Trust, Leeds Hospital Charitable Foundation.
Abstract (Originalsprache)
Inflammation is a key driver in the pathogenesis of cystic fibrosis (CF). We assessed the effectiveness of elexacaftor/tezacaftor/ivacaftor (ETI) therapy on downregulating systemic and immune cell-derived inflammatory cytokines. We also monitored the impact of ETI therapy on clinical outcome. Adults with CF, heterozygous for F508del (n = 19), were assessed at baseline, one month and three months following ETI therapy, and clinical outcomes were measured, including sweat chloride, lung function, weight, neutrophil count and C-reactive protein (CRP). Cytokine quantifications were measured in serum and following stimulation of peripheral blood mononuclear cells (PBMCs) with lipopolysaccharide (LPS) and adenosine triphosphate and analysed using LEGEND plex ™ Human Inflammation Panel 1 by flow cytometry (n = 19). ASC specks were measured in serum and caspase-1 activity and mRNA levels determined from stimulated PBMCs were determined. Patients remained stable over the study period. ETI therapy resulted in decreased sweat chloride concentrations (p < 0.0001), CRP (p = 0.0112) and neutrophil count (p = 0.0216) and increased percent predicted forced expiratory volume (ppFEV1) (p = 0.0399) from baseline to three months, alongside a trend increase in weight. Three months of ETI significantly decreased IL-18 (p< 0.0011, p < 0.0001), IL-1β (p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Leeds Institute of Medical Research, University of Leeds, Leeds, United Kingdom.
- Adult Cystic Fibrosis Unit, St James's University Hospital, Leeds, United Kingdom.
- Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom.
ORCID-Profile: Heledd H Jarosz-Griffiths, Giulia Spoletini, Ian J Clifton, Daniel Peckham
Förderung
- Cystic Fibrosis Trust
- Leeds Hospital Charitable Foundation
Zitieren
APA
Jarosz-Griffiths, H. H., Gillgrass, L., Caley, L. R., Spoletini, G., Clifton, I. J., Etherington, C., Savic, S., McDermott, M. F., & Peckham, D. (2024). Anti-inflammatory effects of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis heterozygous for F508del. PLOS ONE, 19(5), e0304555. https://doi.org/10.1371/journal.pone.0304555
Vancouver
Jarosz-Griffiths HH, Gillgrass L, Caley LR, Spoletini G, Clifton IJ, Etherington C, et al. Anti-inflammatory effects of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis heterozygous for F508del. PLOS ONE. 2024;19(5):e0304555. doi:10.1371/journal.pone.0304555
BibTeX
@article{JaroszGriffiths2024,
author = {Jarosz-Griffiths, Heledd H and Gillgrass, Lindsey and Caley, Laura R and Spoletini, Giulia and Clifton, Ian J and Etherington, Christine and Savic, Sinisa and McDermott, Michael F and Peckham, Daniel},
title = {Anti-inflammatory effects of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis heterozygous for F508del},
journal = {PLOS ONE},
year = {2024},
volume = {19},
number = {5},
pages = {e0304555},
doi = {10.1371/journal.pone.0304555}
}
EUVIMED